537 related articles for article (PubMed ID: 30243478)
21. The route to personalized medicine in bladder cancer: where do we stand?
Massari F; Ciccarese C; Santoni M; Brunelli M; Conti A; Modena A; Montironi R; Santini D; Cheng L; Martignoni G; Cascinu S; Tortora G
Target Oncol; 2015 Sep; 10(3):325-36. PubMed ID: 25634607
[TBL] [Abstract][Full Text] [Related]
22. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
23. Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.
Wu Z; Zhu K; Liu Q; Liu Y; Chen L; Cui J; Guo H; Zhou N; Zhu Y; Li Y; Shi B
Int J Med Sci; 2020; 17(6):762-772. PubMed ID: 32218698
[TBL] [Abstract][Full Text] [Related]
24. Precision Medicine and Personalized Medicine in Cardiovascular Disease.
Currie G; Delles C
Adv Exp Med Biol; 2018; 1065():589-605. PubMed ID: 30051409
[TBL] [Abstract][Full Text] [Related]
25. Developing Precision Medicine for Bladder Cancer.
Guercio BJ; Iyer G; Rosenberg JE
Hematol Oncol Clin North Am; 2021 Jun; 35(3):633-653. PubMed ID: 33958155
[TBL] [Abstract][Full Text] [Related]
26. Advances in risk stratification of bladder cancer to guide personalized medicine.
Matulay JT; Kamat AM
F1000Res; 2018; 7():. PubMed ID: 30109022
[TBL] [Abstract][Full Text] [Related]
27. Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives.
Ohishi T; Koga F; Migita T
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26729098
[TBL] [Abstract][Full Text] [Related]
28. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.
Clinton TN; Chen Z; Wise H; Lenis AT; Chavan S; Donoghue MTA; Almassi N; Chu CE; Dason S; Rao P; Rodrigues JA; Vasani NB; Ridouani F; Rosenberg JE; Bajorin DF; Teo MY; Bochner BH; Berger MF; Ostrovnaya I; Pietzak EJ; Iyer G; Gao SP; Hu W; Al-Ahmadie HA; Solit DB
Cell Rep; 2022 Dec; 41(12):111859. PubMed ID: 36543146
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data.
Peng C; Li A; Wang M
Sci Rep; 2017 Nov; 7(1):15639. PubMed ID: 29142286
[TBL] [Abstract][Full Text] [Related]
30. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.
Kamat AM; Hegarty PK; Gee JR; Clark PE; Svatek RS; Hegarty N; Shariat SF; Xylinas E; Schmitz-Dräger BJ; Lotan Y; Jenkins LC; Droller M; van Rhijn BW; Karakiewicz PI;
Eur Urol; 2013 Jan; 63(1):4-15. PubMed ID: 23083902
[TBL] [Abstract][Full Text] [Related]
31. Precision medicine: In need of guidance and surveillance.
Lin JZ; Long JY; Wang AQ; Zheng Y; Zhao HT
World J Gastroenterol; 2017 Jul; 23(28):5045-5050. PubMed ID: 28811702
[TBL] [Abstract][Full Text] [Related]
32. Genomics and bioinformatics as pillars of precision medicine in oncology.
Canzoneri R; Lacunza E; Abba MC
Medicina (B Aires); 2019; 79(Spec 6/1):587-592. PubMed ID: 31864231
[TBL] [Abstract][Full Text] [Related]
33. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.
Tian Q; Price ND; Hood L
J Intern Med; 2012 Feb; 271(2):111-21. PubMed ID: 22142401
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
35. Preclinical models for bladder cancer therapy research.
Ertl I; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):244-250. PubMed ID: 38630912
[TBL] [Abstract][Full Text] [Related]
36. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
37. Cancer Genetics and Implications for Clinical Management.
Jamieson NB; Chang DK; Biankin AV
Surg Clin North Am; 2015 Oct; 95(5):919-34. PubMed ID: 26315514
[TBL] [Abstract][Full Text] [Related]
38. Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer.
Antoniou P; Ziogas DE; Vlachioti A; Lykoudis EG; Mitsis M; Roukos DH
Per Med; 2019 Sep; 16(5):361-364. PubMed ID: 31507233
[No Abstract] [Full Text] [Related]
39. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
40. New frontiers in therapeutic resistance in cancer.
Sartore-Bianchi A; Delorenzi M; Gagnon-Kugler T; Rousseau C; Batist G
Expert Rev Anticancer Ther; 2012 Jul; 12(7):877-9. PubMed ID: 22845402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
